You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
微創醫療(00853.HK)或配售若干數目新股 預計籌集約2億美元
格隆匯 06-22 18:36

格隆匯 6 月 22日丨微創醫療(00853.HK)發佈公告,公司正考慮就建議配售委聘一名或多名配售代理,據此可能根據公司股東授出的一般授權配售公司將予發行的若干數目的新普通股,並預計籌集約2億美元。由於配售事項未必一定會按擬定進行或可能完全不會進行,故股東及投資者於買賣公司股份或其他證券時務請審慎行事。

自2020年初爆發的新型冠狀病毒肺炎疫情令中國及全球社會面臨嚴峻挑戰。集團一直不時評估疫情對集團於中國及其他地方的營運及業務的整體影響,並努力控制相關影響。

新型冠狀病毒肺炎疫情在全球爆發對集團於2020年上半年的業務造成不利影響。根據目前可獲得的資料,集團於截至2020年5月31日止五個月的收入錄得較2019年同期減少20%至25%(剔除匯率影響),與業內若干可資比較公司大致相符。儘管上文所述,集團於2020年第二季度的收入較第一季度有所改善。在無不可預見的情況下及受多項因素(包括中國及全球新型冠狀病毒肺炎形勢的發展以及市況)的規限,董事會目前預期集團的收入於2020年下半年將會繼續改善,並認為集團於2020年的表現將與2019年的表現基本相符。雖然公司預計集團中國市場的不同業務分部的收入將按不同比率增長,集團若干其他分部的國際業務的收入可能會下滑。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account